Neurocrine Biosciences (NBIX) Earnings Date & Reports

Key Takeaways

• Total revenues climbed 41% year over year to $1.12 billion, while net product sales surpassed $1 billion in a single quarter for the first time.
• Non-GAAP diluted earnings per share (EPS, a profitability measure that excludes certain one-time or non-cash items) came in at $3.29, far above the roughly $1.91 consensus estimate.
• GAAP diluted EPS was $1.96, down 4% from $2.04 a year earlier, reflecting acquisition-related charges and an equity-investment loss.
• INGREZZA net product sales rose 17% to $801 million, and the company raised its full-year 2026 sales guidance for the drug.
• Newer products CRENESSITY and VYKAT XR delivered strong growth, with CRENESSITY sales up 115% year over year.
• Shares rose roughly 6.9% in after-hours trading following the report.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for NBIX.
• To discover more market opportunities, explore Trending AI Robots.

Earnings Context and Why It Matters

Neurocrine Biosciences has spent 2026 transitioning from a company largely defined by its flagship movement-disorder drug, INGREZZA, into a multi-product biopharmaceutical business. The recent acquisition of Soleno Therapeutics added VYKAT XR, a treatment for hyperphagia (excessive hunger) in Prader-Willi syndrome, while CRENESSITY continues to scale in congenital adrenal hyperplasia. This quarter was an important test of whether that broader portfolio could sustain momentum while the company funds a late-stage pipeline that includes candidates for major depressive disorder and schizophrenia. Crossing $1 billion in quarterly product sales marks a meaningful milestone and reinforces investor confidence in the company's growth trajectory.

Reported Results

For the third quarter ended September 30, 2026, Neurocrine Biosciences reported total revenues of $1.12 billion, up 41% from $794.9 million in the prior-year period and above the roughly $1.04 billion consensus estimate. Net product sales reached $1.12 billion. Non-GAAP diluted EPS was $3.29, a 52% increase from $2.17 a year earlier and well ahead of the approximately $1.91 analysts expected. On a GAAP basis, diluted EPS was $1.96, compared with $2.04 in the year-ago quarter.

Product-level results showed broad strength. INGREZZA net product sales rose 17% to $801 million, supported by record total and new prescriptions. CRENESSITY net product sales surged 115% to $211 million, with roughly 80% reimbursement on dispensed prescriptions. VYKAT XR contributed $107 million in its second full quarter under Neurocrine's ownership. Management also raised full-year 2026 INGREZZA sales guidance to a range of $2.90 billion to $2.925 billion, up from $2.825 billion to $2.875 billion previously, while lowering its GAAP and Non-GAAP selling, general, and administrative (SG&A) expense guidance.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking names like Neurocrine Biosciences, it offers a practical way to monitor sector momentum and identify comparable setups.

Market Reaction and Investor Sentiment

The market responded favorably to the results, with Neurocrine shares rising roughly 6.9% in after-hours trading to around $155. The magnitude of the Non-GAAP EPS beat, combined with the raised INGREZZA guidance, appeared to reassure investors after a period of relative weakness that had left the stock down about 9% over the prior three months. The strong CRENESSITY growth trajectory and the early contribution from VYKAT XR reinforced the view that the company is successfully diversifying beyond its flagship product, even as GAAP profitability was pressured by acquisition-related amortization and an unrealized loss on equity investments.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether the company can sustain double-digit prescription growth across INGREZZA, CRENESSITY, and VYKAT XR while managing the integration of the Soleno acquisition. Management signaled that VYKAT XR's growth may be somewhat delayed as it works through real-world safety communication, though it expressed confidence in the product's benefit-risk profile and plans additional studies beginning in 2027.

The pipeline remains a central focus. Neurocrine has initiated a Phase 1 study of NBIP-1968, an investigational triple agonist for obesity, alongside the Phase 1 CRF2 agonist NBIP-2118, with early data intended to guide a potential combination approach. A Phase 2 study of NBI-567, a selective muscarinic agonist for cognition in Alzheimer's disease, is also underway.

Key near-term catalysts include Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, both expected in 2027, as well as the company's R&D Day scheduled for December 15, 2026. Investors will also monitor cost trends, as research and development (R&D) spending continues to rise to support the expanding clinical portfolio.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations